EGFR and non-small cell lung carcinoma: However, no statistically significant differences were observed for diarrhea (RR = 1.15, 95% CI: 0.82-1.62, <i>p</i> = 0.418), and skin rash (RR = 1.35, 95% CI: 0.88-2.07, <i>p</i> = 0.164).<h4>Conclusion</h4>In contrast to WBRT alone, the combination of EGFR-TKI and WBRT significantly improves intracranial response, enhancing the objective response rate, disease control rate, and 1-year survival rate in NSCLC patients with brain metastases.